Anti–CTLA-4 therapy requires an Fc domain for efficacy
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Significance: Ipilimumab, an antibody that recognizes cytotoxic T lymphocyte antigen (CTLA)-4, was the first approved “checkpoint”-blocking anticancer therapy. In mice, the response to antibodies against CTLA-4 depends entirely on expression of the Fcγ receptor. We developed H11, an alpaca heavy chain-only antibody fragment against CTLA-4 that lacks an Fc portion and inhibits interactions between CTLA-4 and its ligand. By using H11 to visualize CTLA-4 expression in the whole animal, we found that accessible CTLA-4 is largely confined to the tumor; however, H11 treatment has minimal effects on antitumor responses. Installing the murine IgG2a constant region on H11 greatly enhances antitumor response. We were thus able to dissociate CTLA-4 blockade from CTLA-4–dependent receptor engagement as an explanation for the antitumor effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 2×
“Anti–CTLA-4 therapy in patients is associated with diverse, severe inflammatory toxicities, including a life-threatening colitis in a substantial fraction of patients (2, 4, 5, 19).”
BackgroundCTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956 · cited 2×
“H11 bound to CTLA-4 in permeabilized spleen cells, showing preferential staining of CD3CD4CD25 T cells, as has been reported for conventional anti–CTLA-4 antibodies (20, 21).”
BackgroundTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 2×
“CTLA-4 is a member of the IgV domain superfamily, and serves as a coinhibitory receptor expressed on regulatory T cells (Tregs) and activated CD4 and CD8 T cells (12, 13).”
BackgroundNanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974 · cited 1×
“Their mechanism of action includes (re)activation of cytotoxic T cells that recognize neoantigens, but the details that link antibody binding to downstream T cell-mediated antitumor responses are not completely understood, particularly for CTLA-4–targeted therapies (7, 8).”
BackgroundSimpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472 · cited 4×
“on expression of the Fcγ receptor (FcγR), which may facilitate antibody-dependent cellular phagocytosis by tumor-associated macrophages (23, 24).”
BackgroundInfluentialDistinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade
Wei, S. C., Levine, J. H., Cogdill, A. P., Zhao, Y., Anang, N.-A. A. S., Andrews, M. C., Sharma, P., Wang, J., Wargo, J. A., Pe’er, D., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.024 · Cited by 1,302
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 10×
“Loss of FcγRIV renders CTLA-4 blockade inert in the B16F10 GVAX model, even though this finding does not exclude a necessary role for FcγRIV in the antitumor response that is not directly related to binding the therapeutic antibody.”
BackgroundMethodInfluentialSelby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857 · cited 3×
“Exchange of the Fc domain on anti–CTLA-4 for one that has low affinity for FcγRs similarly diminishes the therapeutic activity of CTLA-4 blockade in two murine models of colon cancer (25).”
BackgroundArlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669 · cited 1×
“In contrast, PD-1–blocking antibodies may be removed from their targets by FcγR binding, reducing efficacy (40).”
BackgroundSelf-citationHodi, F. S., Butler, M., Oble, D. A., Seiden, M. V., Haluska, F. G., Kruse, A., MacRae, S., Nelson, M., Canning, C., Lowy, I., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712237105 · Cited by 650 · cited 1×
“An increased CD8-to-Treg ratio has been associated with therapeutic responses in patients (35, 42), and the anti–CTLA-4 antibody ipilimumab can deplete human Tregs in vitro (35).”
BackgroundDurable antitumor responses to CD47 blockade require adaptive immune stimulation
Sockolosky, J. T., Dougan, M., Ingram, J. R., Ho, C. C. M., Kauke, M. J., Almo, S. C., Ploegh, H. L., & Garcia, K. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1604268113 · Cited by 366
Self-citation
Cited by
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
Li, A., Yi, M., Qin, S., Song, Y., Chu, Q., & Wu, K. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0721-x · Cited by 413
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 388
Nanobodies: Next Generation of Cancer Diagnostics and Therapeutics
Yang, E. Y., & Shah, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01182 · Cited by 291
Metadata
- Authors
- Ingram, J. R., Blomberg, O. S., Rashidian, M., Ali, L., Garforth, S., Fedorov, E., Fedorov, A. A., Bonanno, J. B., Le Gall, C., Crowley, S., Espinosa, C., Biary, T., Keliher, E. J., Weissleder, R., Almo, S. C., Dougan, S. K., Ploegh, H. L., & Dougan, M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2018-03-26
- Volume
- 115
- Issue
- 15
- Pages
- 3912-3917
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2791782653
- Cited by
- 150
- References
- 16
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.